INVO Fertility, Inc. Common Stock
About: INVO Fertility Inc is a healthcare services fertility company dedicated to expanding assisted reproductive technology (ART) care to patients in need. It is offering the intravaginal culture (IVC) procedure enabled by INVOcell medical device (INVOcell). The INVOcell is a proprietary and revolutionary medical device, and the first to allow fertilization and early embryo development to take place in vivo within the woman's body. The company's segments include: The Clinics Services operating segment consisting of financial information for WFI and the Atlanta Clinic; The INVOcell Device operating segment consisting of financial information relating to the manufacture and sales of the INVOcell; and The Therapeutics segment consisting of financial information relating to acquired subsidiary, NTI.
Employees: 32
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
38% more capital invested
Capital invested by funds: $165K [Q4 2024] → $228K (+$62.8K) [Q1 2025]
12.47% more ownership
Funds ownership: 4.56% [Q4 2024] → 17.03% (+12.47%) [Q1 2025]
33% less funds holding
Funds holding: 9 [Q4 2024] → 6 (-3) [Q1 2025]
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 5
Research analyst outlook
We haven’t received any recent analyst ratings for IVF.
Financial journalist opinion


